Veru (VERU) Cash from Investing Activities (2010 - 2026)
Veru (VERU) posted quarterly Cash from Investing Activities of $3.5 million for Q1 2026, up 206.69% year-over-year from $1.1 million in Q1 2025, and down 43.91% quarter-over-quarter from $6.3 million in Q3 2025.
Veru (VERU) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Cash from Investing Activities for 17 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 206.69% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $10.3 million (down 44.72% YoY), while the FY2025 annual figure was $25.1 million, up 17096.01% from the prior year.
- Cash from Investing Activities eased to $3.5 million in Q1 2026 per VERU's latest filing, from $6.3 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $17.2 million in Q4 2024 and bottomed at -$285565.0 in Q4 2022.
- Historically, Cash from Investing Activities has averaged $2.5 million across 5 years, with a median of $474064.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 3655.58% — and 2025, when it soared 4672.43%.
- Veru's Cash from Investing Activities stood at -$285565.0 in 2022, then surged by 375.64% to $787126.0 in 2023, then jumped by 2090.92% to $17.2 million in 2024, then plunged by 63.61% to $6.3 million in 2025, then plunged by 43.91% to $3.5 million in 2026.
- Business Quant data shows VERU's Cash from Investing Activities at $3.5 million in Q1 2026, $6.3 million in Q3 2025, and $474064.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | 1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.80 Mn |
| Jun 30, 2026 | 1.80 Mn |
| Mar 31, 2026 | 3.52 Mn |
| Mar 31, 2026 | 3.52 Mn |
| Sep 30, 2025 | 6.28 Mn |
| Sep 30, 2025 | 6.28 Mn |
| Jun 30, 2025 | 474,064.00 |
| Jun 30, 2025 | 474,064.00 |
| Mar 31, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 17.25 Mn |
| Dec 31, 2024 | 17.25 Mn |
| Sep 30, 2024 | 131,500.00 |
| Sep 30, 2024 | 131,500.00 |
| Jun 30, 2024 | 55,370.00 |
| Jun 30, 2024 | 55,370.00 |
| Mar 31, 2024 | -40,656.00 |
| Mar 31, 2024 | -40,656.00 |
| Sep 30, 2023 | 787,126.00 |
| Sep 30, 2023 | 787,126.00 |